I
n recent years, personalized therapies have transformed the management of many advanced malignancies. However, despite advances in targeted therapy and immunotherapy that have expanded the treatment options for patients with metastatic kidney cancer, we are unable to predict which patients are most likely to respond to individual treatments. 1 With a number of highly effective therapies available, it is becoming increasingly important to develop a more tailored approach to treatment selection.
In an expert interview, conducted at the American Society of Clinical Oncology (ASCO) Annual
Meeting, which was held from June 1-5, 2018 in Chicago, Illinois, Ulka Vaishampayan discusses the role of personalized therapy in patients with advanced renal cancer and the potential role of X4P-001 in treatment paradigms in the future.
Q. What are the main unmet needs in the treatment of advanced renal cancer?
In the last few years a number of new treatments have emerged for advanced renal cancer but none have been compared head-to-head. Another problem is that we do not have good predictive markers to inform our therapeutic choices.
Q. What factors do you take into account when selecting a therapy for an individual patient with advanced renal cancer?
The two major criteria are the patient characteristics and the tumor characteristics. I consider the 
Q. What are the most useful molecular markers to inform selection of therapy?
Currently there are no validated molecular biomarkers to help us in our therapeutic choices in renal cancer. However, a number of biomarkers are very interesting and showing promising results. The most important is programmed death-ligand 1 (PD-L1). PD-L1 positivity tells us that the patient is more likely to respond to immunotherapy, although, although patients with PD-L1-negative tumors have also benefitted from immunotherapy. 2 The other interesting markers that are being researched are BAP1 mutations and PBRM1 mutations. 3 These have shown the potential to predict response to immunotherapy, or lack thereof. 4 Other possible markers are easily accessible, such as neutrophil/lymphocyte ratio, 5 and the time of response on previous anti-vascular endothelial growth factor (VEGF) therapy. This can be useful when considering immunotherapy in the second-line setting because there is a type of kidney cancer that is likely to be more responsive to the anti-VEGF pathway than to immunotherapy.
Q. What is the mechanism of action of X4P-001?
X4P-001 is an inhibitor of the chemokine receptor CXCR4. CXCR4 overexpression has been shown to play a role in the progression of renal cancer metastases as well as being found in brain metastases. 
Q. Could you tell us

